Abstract: A split-gate enhanced power MOS device includes a substrate and an epitaxial layer formed on an upper surface of the substrate. A control gate trench is provided in the epitaxial layer. The control gate trench includes a gate electrode and a split-gate electrode. The gate electrode includes a first gate electrode and a second gate electrode. The first gate electrode and the second gate electrode are located in an upper half portion of the control gate trench and are separated by a first dielectric layer. The first gate electrode and the second gate electrode are located above the split-gate electrode and are separated from the split-gate electrode by a second dielectric layer. The first gate electrode and the second gate electrode are separated from a body region in the epitaxial layer by a gate dielectric.

Abstract: The present invention relates to a compound for treating or preventing osteoarthritis. The compound relieves the joint pain, inhibits and attenuates the development of post-traumatic osteoarthritis in mouse model. The present invention also provides a pharmaceutical composition comprising the compound for treating or preventing osteoarthritis. The present invention further provides a method for treating or preventing osteoarthritis by administrating to the patient in need thereof with the pharmaceutical composition.

Abstract: Provided herein is a combination product comprising a Bcl-2 inhibitor (or a Bcl-2/Bcl-xl dual inhibitor) and a BTK inhibitor, the combination product providing a use in the prevention and/or treatment of a disease (e.g., cancer, autoimmune disease and inflammatory disease.).

Abstract: A method is provided of receiving user data from multiple transmitters, the user data from each transmitter having been encoded as a Low Density Lattice codeword, and the multiple Low Density Lattice codewords having been transmitted so as to be received as a combined signal at a receiver, the method of receiving comprising the steps of: (i) receiving the signal, (ii) calculating coefficients of linear combinations of the codewords from the multiple transmitters, (iii) calculating a scaling factor to be applied to the signal based on the coefficients, (iv) applying the scaling factor to the signal to provide a linear combination of the codewords, (v) decoding the linear combination of the codewords based on channel state information to obtain an optimal independent linear combination of user data, (vi) repeating steps (ii), (iii) (iv) and (v) to obtain at least as many optimal independent linear combinations as the number of transmitters, and recovering the user data from the optimal independent linear combin

Abstract: There is a need for solutions that predictive data analytics with improved training efficiency and/or accuracy. This need can be addressed by, for example, processing an original feature entry to generate a group of low-order feature values, including performing a first number of iterations of a feature engineering transformation to generate a group of engineered feature values and determining the group of low-ordered feature values based on a number of feature values from the group of engineered feature values; processing the original feature entry to generate a group of high-order feature values; merging the group of low-order feature values and the group of high-order feature values to generate a processed feature entry corresponding to the original feature entry; and providing the processed feature entry as an input to a prediction unit.

Abstract: Embodiments of the present disclosure provide methods, systems, apparatuses, and computer program products for generating, training, and utilizing a digital signal processor (DSP) to evaluate graph data that may include irregular grid graph data. An example DSP that may be generated, trained, and used may include a set of hidden layers, wherein each hidden layer of the set of hidden layers comprises a set of heterogeneous kernels (HKs), and wherein each HK of the set of HKs includes a corresponding set of filters selected from the constructed set of filters and associated with one or more initial Laplacian operators and corresponding initial filter parameters.

Abstract: A method is provided of receiving user data from multiple transmitters, the user data from each transmitter having been encoded as a Low Density Lattice codeword, and the multiple Low Density Lattice codewords having been transmitted so as to be received as a combined signal at a receiver, the method of receiving comprising the steps of: (i) receiving the signal, (ii) calculating coefficients of linear combinations of the codewords from the multiple transmitters, (iii) calculating a scaling factor to be applied to the signal based on the coefficients, (iv) applying the scaling factor to the signal to provide a linear combination of the codewords, (v) decoding the linear combination of the codewords based on channel state information to obtain an optimal independent linear combination of user data, (vi) repeating steps (ii), (iii) (iv) and (v) to obtain at least as many optimal independent linear combinations as the number of transmitters, and recovering the user data from the optimal independent linear combin

Abstract: The present invention relates to methods for preparing patchoulol, ?-santalene, and sclareol in transgenic moss cells that include heterologous nucleic acid molecules encoding a polypeptide or synthase capable of using FPP or GGPP as a substrate. Methods for producing the transgenic moss cell, as well as the transgenic moss cell itself are also disclosed.

Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (“CAT”). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.

Abstract: The invention include glycopeptides having a glycoside and a peptide covalently bound through an amide bond. The glycopeptides may also include a diagnostic or therapeutic agent bound to the glycopeptide. A metal, such as a radionuclide, may also be chelated to the glycopeptide. Specific embodiments of the invention relate to glycopeptides made of chitosan covalently bound to a poly(amino acid) such as poly(glutamic acid) or poly(aspartic acid). Diagnostic agents conjugated to the glycopeptide may facilitate imaging. Specific therapeutic agents that may be conjugated to the glycopeptide include anticancer drugs, rheumatoid arthritis drugs, anticoagulants, anti-angiogenesis drugs, apoptosis drugs, osteoporosis drugs, steroids, and anti-inflammatory drugs. Some agents, such as radionuclides, may have both diagnostic and therapeutic effects.

Abstract: A method of synthesizing a polysaccharide conjugate used for cancer therapy is provided. The method comprises the following steps. A polysaccharide having at least one reactive functional group is provided. The polysaccharide is reacted with at least one monomeric amino acid having an O-group, such that the at least one monomeric amino acid is covalently bound to the polysaccharide by reacting with the reactive functional group to form an amide bond. At least one metal is conjugated to the at least one monomeric amino acid through the O-group so as to form the polysaccharide conjugate. Furthermore, a method for cancer therapy that uses the polysaccharide conjugate obtained by the method above for treatment is also described.

Abstract: The current disclosure, in one embodiment, includes a polysaccharide conjugate. This conjugate has a polysaccharide and at least one monomeric amino acid having an O-group covalently bound to the polysaccharide. The conjugate also has at least one metal conjugated by the O-group of the amino acid. According to another embodiment, the disclosure provides a method of synthesizing a polysaccharide conjugate by covalently bonding a monomeric amino acid having an O-group to a polysaccharide and by conjugating a metal to the O-group to form a polysaccharide conjugate. According to a third embodiment, the disclosure relates to a method of killing a cancer cell by administering to the cell an effective amount of a polysaccharide conjugate. This conjugate has a polysaccharide and at least one monomeric amino acid having an O-group covalently bound to the polysaccharide. The conjugate also has at least one metal conjugated by the O-group of the amino acid.

Abstract: The present disclosure relates to compounds that act as agonists of, or otherwise modulate the activity of, GPR131 and to their use in the treatment of various diseases. In particular embodiments, the structure of the compounds is given by Formula I: wherein the variables are as described herein. Related compositions, formulations and methods for the preparation of compounds of formula I are also described.

Abstract: Novel methods of synthesis of ethylenedicysteine-sugar conjugates and therapeutic and diagnostic applications of such conjugates are disclosed. Methods of synthesizing these conjugates in high purity are also presented as using starting materials such as thiazolidine carboxylic acid. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these conjugates prepared herein, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

Abstract: A razor handle includes an at least partially hollow elongated structure and an at least partially hollow sleeve. The elongated structure has an interior surface and an exterior surface, a first opening at a proximate end, and a second opening along a length of the elongated structure. The sleeve has an interior surface and an exterior surface with a protrusion. The protrusion is adapted to extend through the second opening to the exterior surface of the elongated structure forming a gripping member.

Abstract: Methods and compositions are provided for assessing, treating, and preventing diseases, especially cancer, using cancer-associated targets (“CAT”). Methods and compositions are also provided for determining or predicting the effectiveness of a treatment for these diseases or for selecting a treatment, using CAT. Methods and compositions are further provided for modulating cell function using CAT. Also provided are compositions that modulate CAT (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate CAT, and agents identified by these screening methods.

Abstract: The present invention relates to methods for preparing patchoulol, ?-santalene, and sclareol in transgenic moss cells that include heterologous nucleic acid molecules encoding a polypeptide or synthase capable of using FPP or GGPP as a substrate. Methods for producing the transgenic moss cell, as well as the transgenic moss cell itself are also disclosed.

Abstract: The invention provides, in a general sense, a new labeling strategy employing compounds that are N2S2 chelates conjugated to a targeting ligand, wherein the targeting ligand is a disease cell cycle targeting compound, a tumor angiogenesis targeting ligand, a tumor apoptosis targeting ligand, a disease receptor targeting ligand, amifostine, angiostatin, monoclonal antibody C225, monoclonal antibody CD31, monoclonal antibody CD40, capecitabine, a COX-2 inhibitor, deoxycytidine, fullerene, herceptin, human serum albumin, lactose, leuteinizing hormone, pyridoxal, quinazoline, thalidomide, transferrin, or trimethyl lysine. The present invention also pertains to kits employing the compounds of interest, and methods of assessing the pharmacology of an agent of interest using the present compounds.

Abstract: Isolated human multipotent adult stem cell and isolated populations of cells that include human multipotent adult stem cells are disclosed. Human hair-follicle derived multipotent adult stem cells and methods of preparing isolated populations of cells that include human multipotent adult stem cells are disclosed. Isolated human hair-follicle derived multipotent adult stem cell that can differentiate in culture into a neuronal cell, a glial cell, a melanocyte cell, a muscle cell, an osteocyte, a chondrocyte, and a lymphocyte. Isolated human hair-follicle derived multipotent adult stem cell that can grow in cell culture in spheres are disclosed.

Abstract: Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control.